Ono Pharmaceutical (OTCMKTS:OPHLF) Issues Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) issued its quarterly earnings results on Monday. The company reported $0.21 EPS for the quarter, Zacks reports. Ono Pharmaceutical had a net margin of 19.64% and a return on equity of 11.85%.

Ono Pharmaceutical Stock Performance

OTCMKTS:OPHLF opened at $9.22 on Tuesday. The firm has a 50-day simple moving average of $10.38 and a 200-day simple moving average of $12.49. Ono Pharmaceutical has a one year low of $9.22 and a one year high of $16.82. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.80 and a current ratio of 3.22. The firm has a market cap of $4.33 billion, a P/E ratio of 6.88 and a beta of 0.59.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.